GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Peramivir (Rapivab, adults)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

UCSF peramivir - repeated-dose and dialysis schedules

Product / population
Adult uncomplicated influenza with no more than 2 days of symptoms; intravenous peramivir. Institutional repeated dosing is a separately labeled alternative, not the single-dose label course.
Renal method
CrCl mL/min; IHD and continuous hemodialysis
Source revision
Revision date not stated on the reviewed page.
Retrieved
2026-09-05
Local review status
Separate professional-source protocol; not automatically equivalent to product labeling.
Professional

UCSF peramivir - repeated-dose and dialysis schedules

Open original reference

University of California San Francisco (UCSF) · Adult uncomplicated influenza with no more than 2 days of symptoms; intravenous peramivir. Institutional repeated dosing is a separately labeled alternative, not the single-dose label course.

Renal method: CrCl mL/min; IHD and continuous hemodialysis
Source date: Revision date not stated on the reviewed page.
Retrieved: 2026-09-05

Separate professional-source protocol; not automatically equivalent to product labeling.

Source-specific renal protocol

Printed CrCl band (mL/min)UCSF IV schedule
>50600 mg every 24 hours
30-50200 mg every 24 hours
10-30100 mg every 24 hours
<10100 mg once, then 15 mg every 24 hours

IHD: 100 mg on day 1, then 100 mg two hours after each session. Continuous dialysis: consult ID pharmacy.

RDM31-peramivir-prof-1 · Source locator: Adult and intermittent/continuous hemodialysis tables

Source-specific limits

This is repeated institutional dosing, not the U.S. single-dose uncomplicated-influenza regimen. The printed ranges overlap at 30 and differ at 50 from the label. Confirm an exact-boundary plan with ID pharmacy; do not silently reassign it.

Source identity and provenance
Source
https://idmp.ucsf.edu/content/peramivir
Retrieved
2026-09-05
Renal-function method
CrCl mL/min; IHD and continuous hemodialysis
Source date/version
Revision date not stated on the reviewed page.
Hash meaning
SHA-256 identifies the local paraphrase, not original source bytes.
Local summary SHA-256
2b62ae9afc29bbc45ef0b1644d649ffbb0fe315ff4a61e9fa5213a69c075b871

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=peramivir&s1=RDM31-prof-peramivir-1&h1=81ef3ce3c5ef833d8505cdd818f4e9a7a693dd4909830591edde3f886a63a880